NASDAQ · ALNY
Alnylam Pharmaceuticals, Inc.
$174.00-$58.40 (-25.13%)
Alnylam Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.73% below the high.
Loading market information…
NASDAQ · SRPT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Sarepta Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 56.43% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Sarepta Therapeutics, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of $0.07. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sarepta Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 6, 2025 | -$4.60-428.74% vs estimate | $744.86M+8.35% vs estimate |
|---|
| Q4 2024 | Feb 26, 2025 | $1.50+8.7% vs estimate | $658.41M+4.34% vs estimate |
|---|
| Q3 2024 | Nov 6, 2024 | $0.34+670.18% vs estimate | $467.17M+14.74% vs estimate |
|---|
THE ANALYST VIEW
55 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 5 contributors · Median target $20.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$174.00-$58.40 (-25.13%)
Alnylam Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.73% below the high.
$44.39-$0.51 (-1.14%)
Ionis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.82% below the high.
$64.46+$1.44 (+2.28%)
PTC Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.06% below the high.
$17.04+$0.06 (+0.35%)
Dyne Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.61% below the high.
$13.23-$0.09 (-0.68%)
Intellia Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 28.41% below the high.
$3.63-$0.01 (-0.27%)
Wave Life Sciences Ltd.’s quoted price sits in the lower half of its reported 52-week range, 83.29% below the high.
$11.06-$0.02 (-0.18%)
Design Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.88% below the high.
$6.39-$0.09 (-1.39%)
Solid Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.19% below the high.
